Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 9, 2022

Primary Completion Date

May 31, 2025

Study Completion Date

December 31, 2025

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG

Anlotinib

Anlotinib 8mg or 10mg, d1-9，q2w

DRUG

Penpulimab

Penpulimab 200mg, d6, q2w

DRUG

Irinotecan

Irinotecan 180mg/m2, d6, q2w

Trial Locations (1)

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER